The stock of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) is a huge mover today! About 127,880 shares traded hands. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has risen 13.31% since March 8, 2016 and is uptrending. It has outperformed by 4.00% the S&P500.
The move comes after 6 months negative chart setup for the $413.90M company. It was reported on Oct, 11 by Barchart.com. We have $9.81 PT which if reached, will make NASDAQ:OMED worth $41.39 million less.
Analysts await Oncomed Pharmaceuticals Inc (NASDAQ:OMED) to report earnings on November, 3. They expect $-0.77 EPS, up 4.94% or $0.04 from last year’s $-0.81 per share. After $-0.91 actual EPS reported by Oncomed Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -15.38% EPS growth.
Oncomed Pharmaceuticals Inc (NASDAQ:OMED) Ratings Coverage
Out of 8 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 7 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 88% are positive. OncoMed Pharmaceuticals has been the topic of 11 analyst reports since September 9, 2015 according to StockzIntelligence Inc. Cantor Fitzgerald initiated it with “Buy” rating and $16 target price in Monday, April 18 report. The company was initiated on Friday, December 4 by Wells Fargo. H.C. Wainwright initiated it with “Buy” rating and $20 target price in Thursday, September 22 report. The stock of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) earned “Buy” rating by Jefferies on Wednesday, September 9. The stock of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) earned “Buy” rating by Jefferies on Wednesday, August 10. Mizuho maintained it with “Buy” rating and $15 target price in Tuesday, January 26 report. The company was downgraded on Monday, January 25 by Leerink Swann. Mizuho maintained the stock with “Neutral” rating in Wednesday, January 6 report. JMP Securities maintained Oncomed Pharmaceuticals Inc (NASDAQ:OMED) on Wednesday, March 9 with “Market Outperform” rating. The firm has “Outperform” rating by BMO Capital Markets given on Tuesday, April 12.
According to Zacks Investment Research, “OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States.”
Insitutional Activity: The institutional sentiment decreased to 1.63 in 2016 Q2. Its down 0.10, from 1.73 in 2016Q1. The ratio fall, as 10 funds sold all Oncomed Pharmaceuticals Inc shares owned while 14 reduced positions. 9 funds bought stakes while 30 increased positions. They now own 9.23 million shares or 8.05% more from 8.54 million shares in 2016Q1.
Franklin Res, a California-based fund reported 293,900 shares. Vanguard Group owns 632,093 shares or 0% of their US portfolio. Jpmorgan Chase owns 6,060 shares or 0% of their US portfolio. Moreover, Strs Ohio has 0% invested in Oncomed Pharmaceuticals Inc (NASDAQ:OMED) for 24,000 shares. Teachers Advisors last reported 27,462 shares in the company. The North Carolina-based Comml Bank Of America Corporation De has invested 0% in Oncomed Pharmaceuticals Inc (NASDAQ:OMED). Int Gp accumulated 0% or 10,084 shares. Qs Invsts Limited Liability Com accumulated 0.01% or 64,307 shares. Goldman Sachs Grp Incorporated owns 27,092 shares or 0% of their US portfolio. Product Prtnrs Ltd Liability, a New York-based fund reported 24,500 shares. The New York-based Blackrock has invested 0% in Oncomed Pharmaceuticals Inc (NASDAQ:OMED). Fmr Ltd Liability Corporation, a Massachusetts-based fund reported 911,303 shares. Blackrock Advsrs Ltd Limited Liability Company accumulated 18,316 shares or 0% of the stock. Iguana Mngmt Ltd, a New York-based fund reported 632,200 shares. Granite Point Mngmt L P reported 91,850 shares or 0.49% of all its holdings.
More news for Oncomed Pharmaceuticals Inc (NASDAQ:OMED) were recently published by: Fool.com, which released: “Why Oncomed Pharmaceuticals Inc’s Share Price (but Not Its Valuation …” on August 18, 2016. Fool.com‘s article titled: “Why OncoMed Pharmaceuticals’ Stock Crashed Today” and published on January 25, 2016 is yet another important article.
OMED Company Profile
OncoMed Pharmaceuticals, Inc. (OncoMed), incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Firm focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.